BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI)

Q1 2016 13F Holders as of 31 Mar 2016

Type / Class
Equity / COM NEW
Total 13F shares
1,693,610
Share change
+197,655
Total reported value
$4,520,000
Price per share
$2.68
Number of holders
25
Value change
+$523,605
Number of buys
9
Number of sells
5

Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q1 2016

As of 31 Mar 2016, BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by 25 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 1,693,610 shares. The largest 10 holders included SABBY MANAGEMENT, LLC, VANGUARD GROUP INC, PERCEPTIVE ADVISORS LLC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., NORTHERN TRUST CORP, A.R.T. Advisors, LLC, Psagot Investment House Ltd., and SUSQUEHANNA INTERNATIONAL GROUP, LLP. This page lists 25 institutional shareholders reporting positions in this security for the Q1 2016 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.